2016
DOI: 10.2147/jhc.s106072
|View full text |Cite
|
Sign up to set email alerts
|

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

Abstract: Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for the treatment of advanced HCC. Tivantinib (ARQ-197), a non-ATP competitive inhibitor of cellular mesenchymal–epithelial transcription factor (c-MET), has shown a survival benefit in patients with advanced HCC who have fa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
19
0
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(21 citation statements)
references
References 45 publications
1
19
0
1
Order By: Relevance
“…[83][84][85] It is well known that binding of HGF to c-MET induced the activation of multiple downstream metabolic pathways, including the mTOR pathway. 86 Our results extended our knowledge about HGF/c-MET in drug metabolism. Sorafenib is the first-class molecular targeted drug for advanced HCC approved by the US Food and Drug Administration.…”
Section: Discussionsupporting
confidence: 76%
“…[83][84][85] It is well known that binding of HGF to c-MET induced the activation of multiple downstream metabolic pathways, including the mTOR pathway. 86 Our results extended our knowledge about HGF/c-MET in drug metabolism. Sorafenib is the first-class molecular targeted drug for advanced HCC approved by the US Food and Drug Administration.…”
Section: Discussionsupporting
confidence: 76%
“…Thus, further study should focus on high-MET patients. Based on these findings, two randomized double-blind placebo-controlled phase III trial (NCT01755767 and NCT02029157) are ongoing to evaluate tivantinib in patients with MET-high advanced HCC, with the primary endpoints of OS and PFS, respectively [ 99 ].…”
Section: Targeted Therapies For Hccmentioning
confidence: 99%
“…However, surprisingly, two large randomised double-blind placebo-controlled phase III trials i.e. METIV-HCC (NCT01755767) and JET-HCC (NCT02029157), have both failed to demonstrate improved OS in advanced HCC patients with high c-met protein expression [46].…”
Section: C-met Inhibitorsmentioning
confidence: 99%